– SWITZERLAND, Geneva – Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that it has appointed Dr Sanjeev Kanoria as Non-Executive Director, with immediate effect. Dr Kanoria brings with him years of valuable experience, both as a surgeon and as a successful healthcare focussed businessman.
Dr Kanoria is a qualified surgeon, having trained in Kings College and Royal Free Hospital London. He has worked for over 15 years in the area of liver transplant and Hepato-pancreato-biliary surgery and is a Fellow of the Royal College of Surgeons as well as being included on the General Medical Council Specialist Register. Dr Kanoria has a PhD from University College London, for innovative research in reducing liver injury. His academic work has been published in numerous international journals and he has received numerous awards for his pioneering work in reducing liver injury. Dr Kanoria received an MBA from London business school in 1997, before joining McKinsey & Co as a senior consultant in strategy & finance. In 1999 Sanjeev left McKinsey to start his own company, Advinia Health Care, building a chain of nursing homes across the UK, which now employs close to 1,000 people.
In 2013, Sanjeev acquired 100% of the shares of Hypo Alpe-Adria-Bank AG (renamed Austrian Anadi Bank AG), one of the oldest mortgage banks in Austria, through his holding company, Anadi Financial Holdings. Sanjeev has been appointed as the Vice Chairman of the Supervisory Board of Austrian Anadi Bank following FMA approval. The bank has a total asset base of over €3 billion and 16 branches in Austria. He is currently setting up a $200m multi-specialty hospital in Mumbai for cancer and trauma surgery, due to be commissioned in August 2015.
Commenting, Sanjeev Pandya, CEO, said: “I am greatly looking forward to working with Dr Kanoria and know that his vast knowledge and experience of the medical world will help to guide Advanced Oncotherapy into a strong future. Having been in both the medical and business side of the industry, Sanjeev has a rare perspective which will be invaluable to use and gain from. Sanjeev also brings strong connections in Asia which are highly relevant for us given the strong geographic demand for proton therapy in this key part of the world.”
Dr Kanoria commented on his appointment saying: “I am truly looking forward to working with such an experienced team. Advanced Oncotherapy is a unique business which is really pushing the boundaries of the medical world and I am pleased to be part of it, both as a shareholder and now as member of the Board. I look forward to offering both medical and business support from my own experience and knowledge of the industry. This is truly cutting edge medical technology and being part of it is a privilege.”
About Advanced Oncotherapy Plc
Advanced Oncotherapy’s team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.